Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA1 | P00915 | 11/20 | 1.00 |
| ▸ | CA9 | Q16790 | 11/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18300723 | 0.85 | MAPT (1.00) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL671914 | 0.85 | CA2 (1.00) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL4548109 | 0.83 | CA12 (0.71) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL674020 | 0.83 | CA2 (1.00) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL32689896 | 0.83 | CA12 (0.71) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL3460321 | 0.83 | CXCR2 (0.73) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL15133011 | 0.81 | CA12 (0.69) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL12305612 | 0.80 | MAPT (0.70) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL672979 | 0.80 | CA2 (1.00) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL21796365 | 0.78 | APP (0.71) | CA2CA1CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771488-B1 | CARBONIC ANHYDRASE IX-RELATED MARKERS AND USE THEREOF | SIGNALCHEM LIFESCIENCES CORP (CA) | 2018-03-28 | — | — | EP | claimed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | claimed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | claimed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | claimed |
| EP-3297623-B1 | TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY TARGETING APE1/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES | UNIV INDIANA RES & TECH CORP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10772859-B2 | Methods of targeting APE/Ref-1 to inhibit hypoxia signaling genes | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| US-20180200213-A1 | METHODS OF TARGETING APE/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-07-19 | — | — | US | disclosed |
| US-20180200213-A1 | METHODS OF TARGETING APE/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-07-19 | — | — | US | disclosed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| WO-2016186853-A1 | METHODS OF TARGETING APE1/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-11-24 | — | — | WO | disclosed |
| US-9463171-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| US-9463171-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA9 25/4885 |
| US-10772859-B2 | Methods of targeting APE/Ref-1 to inhibit hypoxia signaling genes | HIF1AN, APEX1, HIF1A | CA2 1440/4885CA1 1227/4885CA9 1857/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA9 25/4885 |
| US-20180200213-A1 | METHODS OF TARGETING APE/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES | HIF1AN, APEX1, HIF1A | CA2 1440/4885CA1 1227/4885CA9 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.